Artiva (ARTV) Director Elizabeth Hougen Receives 13,750-Share Award

What Happened

• Elizabeth L. Hougen, a director of Artiva Biotherapeutics, was granted a derivative award recorded as 13,750 shares on 2026-09-08. The filing shows an acquisition at $0.00 (total $0), indicating a grant/option award rather than an open-market purchase.

Key Details

• Transaction date: 2026-09-08 (Form filed the same day).
• Transaction type/code: A = Award/Grant (derivative).
• Shares involved: 13,750 shares (derivative award); acquisition price reported as $0.00.
• Shares owned after transaction: Not disclosed in the provided filing.
• Footnote: The shares subject to the option vest in full on the earlier of September 8, 2027 or the date of the issuer's 2027 annual stockholder meeting.
• Timeliness: Filing date matches the transaction date, indicating a timely report.

Context

• This is a compensation-style grant to a director (common for board service) and not an immediate cash purchase or sale. As a derivative award, value and incentive depend on future vesting and any exercise/strike price (not detailed in the excerpt). Such grants are routine and do not by themselves indicate the director is buying or selling shares for market exposure.